Active, not recruitingPhase 2NCT05387915
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Studying Squamous cell carcinoma of the oropharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Emory University
- Principal Investigator
- James E Bates, MDEmory University Hospital/Winship Cancer Institute
- Intervention
- Radiation Therapy(radiation)
- Enrollment
- 33 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (3)
- Emory University Midtown Hospital, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05387915 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the oropharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06915038ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the OropharynxIndiana University
- RECRUITINGPHASE1NCT06747390Intratumoral Lidocaine Injection Before Oropharyngeal Cancer SurgeryRyan Carey
- RECRUITINGPHASE2NCT06702033The Minimalist Trial-2Washington University School of Medicine
- RECRUITINGPHASE1NCT06589609Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal CancerBlueSky Immunotherapies GmbH
- RECRUITINGPHASE2NCT06223568Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05582122SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal CancersUNICANCER
- ACTIVE NOT RECRUITINGNCT06592716Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?Rigshospitalet, Denmark
- RECRUITINGPHASE2NCT06323460Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerOhio State University Comprehensive Cancer Center
See all trials for Squamous cell carcinoma of the oropharynx →